03 March 2010
Sukaina Virji
sukaina.virji@informa.com
NicOx has signed a licensing agreement which grants Bausch & Lomb exclusive worldwide rights to develop and commercialise NCX 116, a nitric oxide-donating prostaglandin F2α-analogue, which has completed two Phase II studies in patients with glaucoma and ocular hypertension.
Under the...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Pfizer in revised deal on glaucoma implant drug worth up to $168M for pSivida
- Xoma to use acquired Servier hypertension drug to establish a US commercial operation
- Apricus signs further partners for Vitaros and MycoVa
- Aveo licences preclinical RON-targeted antibodies to J&J, for $15 million up front
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
